期刊文献+

注射用地塞米松固体脂质纳米粒冻干粉末的处方与工艺研究及质量评价 被引量:3

Formulation,Technology and Quality Evaluation of Dexamethasone Solid Lipid Nanoparticles Lyophilized Injection
原文传递
导出
摘要 目的:研究注射用地塞米松(DXM)固体脂质纳米粒(SLN)冻干粉末的处方及工艺并评价其质量。方法:优选支架剂处方,确定冻干工艺制备冻干制剂;采用高效液相色谱法测定其中DXM的含量,并对其质量进行研究。结果:以3%甘露醇作为支架剂,DXM-SLN的粒径为340nm,Zeta电位为-25.2mV,包封率为92.10%,载药量为7.10%,于2-8℃环境下可保存3个月。结论:该制备工艺简便、可行,质量控制方法准确、可靠。 OBJECTIVE: To study the formulation and technology of dexamethasone solid lipid nanoparticles(DXMSLN) lyophilized injection and evalnate it' s quality. METHODS: The formulation of the supporting agent was optimized and the preparation technology of lyophilized injection was established to prepare the lyophilised injection. The content of DXM in the sample was determined and its quality was investigated as well. RESULTS: 30% mannitol was supporting agent, the particle size of DXM SLN was 340 nm, with zeta potential at - 25.2 mV, entrapment ratio at 92.10% and drug- loading at 7.10%. It was stable within 3 months' at 2-8 ℃ storing. CONCLUSION: The preparation technique of this preparation is simple and feasible and its quality is stable and controllable.
出处 《中国药房》 CAS CSCD 北大核心 2008年第16期1234-1235,共2页 China Pharmacy
基金 深圳市科技计划资助项目(200602154)
关键词 地塞米松 固体脂质纳米粒 注射用冻干粉末 Dexamethansone Solid lipid nanoparticles Sterile powder for injection
  • 相关文献

参考文献5

二级参考文献10

共引文献10

同被引文献22

  • 1李文华,宋志芳.糖皮质激素在急性肺损伤/急性呼吸窘迫综合征应用中的新进展[J].中华急诊医学杂志,2005,14(5):435-437. 被引量:12
  • 2简炎林,黄园,龚涛.优化地塞米松类脂纳米粒的制备工艺[J].华西药学杂志,2006,21(4):368-370. 被引量:4
  • 3Todo H, Okamoto H, Lida K, et al. Effect of additives on insulin absorption from intratracheally administered dry powders in rats[J], lntJPharm, 2001, 220(1-2) : 101.
  • 4Todo H, Okamoto H, Lida K, et al. Improvement of stability and absorbability of dry insulin powder for inhalation by powder-combination technique [J]. lnt J Pharm, 2004,271(1-2) :41.
  • 5Fridrum R The development of a cascade impactor simulator based on adhesion force measurement to aid the development of dry powder inhalations [J]. Chem Pharm Bull, 1997,45(5):911.
  • 6Toshiomi N, Hiromitsu Y, Atsuo O, et al. Formulations development of inhalation powders for FK888 with carrier lactose using Spinhaler and its absorption in healthy volunteers [J]. J Control Release, 2004,97( 1 ) : 19.
  • 7Gervelas C, Serandour AE, Geiger S, et al. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium[J]. J Control Release, 2007, 118(1):78.
  • 8Li HY, Neill H, Innocent R, et al. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy[J]. J Drug Target, 2005;, 11 ( 7 ) : 425.
  • 9Hao-Ying Li, James Birchall.Chitosan-modified dry powder formulations for pulmonary gene delivery[J].Pharmaceutical Research, 2006,23 ( 5 ) : 941.
  • 10Li HY, Seville PC, Williamson I J, et al. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy[J]. J Gene Med, 2005,7 (3): 343.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部